https://www.selleckchem.com/products/apd334.html
ervention under general anaesthesia or advanced life support, seems to be an independent risk factor for stricture recurrence. Recently, selective internal radiation therapy using yttrium-90 (Y9 glass microspheres (TheraSphere™) was approved for reimbursement by health authorities in France. The PROACTIF study aims to gather data on effectiveness, patient quality of life, and safety with use of Y90 glass microspheres in real-world clinical settings in France. Patient with a diagnosis of hepatocellular carcinoma (HCC), intrahepatic chol
Like
Comment
Share
